MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

10719	Companies
229677	Keywords
158202	Articles
121981	Press releases

Home
Companies
MIRA Pharmaceuticals

PRESS RELEASE

published on 07/22/2024 at 14:00, 1 year 11 months ago

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance
MIRA Pharmaceuticals reveals new promising preclinical data for Ketamir-2, a novel oral ketamine analog, indicating potential advantages for treating neurological and neuropsychiatric disorders

Preclinical Study Neurological Disorders MIRA Pharmaceuticals Neuropsychiatric Disorders Ketamir-2
BRIEF

published on 07/15/2024 at 13:05, 1 year 11 months ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

Pharmaceuticals Preclinical Studies MIRA-55 Anxiety Treatment THC Comparison
BRIEF

published on 07/15/2024 at 13:05, 1 year 11 months ago

Mira Pharmaceuticals annonce des résultats prometteurs pour MIRA-55 dans plusieurs tests précliniques par rapport au THC

Médicaments Etudes Précliniques MIRA-55 Traitement De L'anxiété Comparaison Du THC
PRESS RELEASE

published on 07/15/2024 at 13:00, 1 year 11 months ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC
MIRA Pharmaceuticals, Inc. confirms promising findings on new oral pharmaceutical marijuana analog, MIRA-55, as a potential treatment for neurological and neuropsychiatric disorders. Comparison to THC shows enhanced efficacy and consistent anxiolytic effects

Neurological Disorders Preclinical Studies MIRA-55 MIRA Pharmaceuticals Neuropsychiatric Disorders

Accesswire

Published on 07/14/2026 at 22:30, 2 hours 20 minutes ago

Hillcrest Energy Technologies Announces Board and Leadership Changes Following 2026 Annual General Meeting
Published on 07/14/2026 at 22:30, 2 hours 20 minutes ago

Loop Industries Reports First Quarter Fiscal 2027 Results and Provides Update on Progress Towards Commercialization
Published on 07/14/2026 at 16:40, 8 hours 10 minutes ago

AIAI Holdings' MediGuide Enters the State-of-the-Art Medicine Market With AI-Driven Innovation
Published on 07/14/2026 at 15:45, 9 hours 5 minutes ago

Silver Storm Commences Hot Commissioning of the La Parrilla Sulphide Circuit, Amends the Samsung Prepayment Agreement, and Secures US$5 Million Loan from First Majestic
Published on 07/14/2026 at 15:15, 9 hours 35 minutes ago

Gratomic Inc. Provides Corporate Update for Shareholders

View all ACCESSWIRE

EQS Group

Published on 07/14/2026 at 23:48, 1 hour 2 minutes ago

North Peak Announces Proposed Extension of Warrant Expiry Date
Published on 07/14/2026 at 19:14, 5 hours 36 minutes ago

EQS-Adhoc: Nagarro SE: BaFin Enforcement Review of the 2022 Consolidated Financial Statements
Published on 07/14/2026 at 18:17, 6 hours 33 minutes ago

EQS-Adhoc: Delivery Hero confirms advanced negotiations with Uber Technologies in respect to potential takeover offer
Published on 07/14/2026 at 17:51, 6 hours 58 minutes ago

Aumann announces share buyback with an allotment ratio of approximately 6%
Published on 07/14/2026 at 17:30, 7 hours 20 minutes ago

NABR: The U.S. Fish and Wildlife Service for the Second Time Rejects Activists' Petition to List Long-Tailed Macaque Monkeys Under the Endangered Species Act

Les Echos

Published on 07/13/2026 at 18:00, 1 day 6 hours ago

CP Icade - Icade reprend 100% de la propriété de la Tour Eqho à la Défense
Published on 07/13/2026 at 18:00, 1 day 6 hours ago

PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
Published on 07/13/2026 at 18:00, 1 day 6 hours ago

THERMADOR GROUPE : 2026 half-year turnover
Published on 07/13/2026 at 18:00, 1 day 6 hours ago

THERMADOR GROUPE : publication du chiffre d'affaires semestriel 2026
Published on 07/13/2026 at 17:45, 1 day 7 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE